Edelman Joseph's Form 4 filing
Cerevel Therapeutics Holdings, Inc.CERE · filed Oct 17, 2023
- Accession no.
- 0001062993-23-019470
- Filed
- Oct 17, 2023, 4:53 PM ET
- Trade date
- Oct 16, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $20.0M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Edelman JosephCIK 0001164426 | Director |
| Perceptive Advisors LLCCIK 0001224962 | Director |
| Perceptive Life Sciences Master Fund LtdCIK 0001249675 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 16, 2023 | Common Stock | PPurchaseAcquired | +876,808 | $22.81 | +$19,999,990.48 | 10,794,876 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.